NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
Bristol-Myers Squibb
GlaxoSmithKline
Pharmacyclics LLC.
National Cancer Institute (NCI)